Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 2 countries.
Shay WeissDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Kamran WaidhaThe Shraga Segal Department of Microbiology, Immunology & Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel.ORCID 0000-0002-0665-9370
Saravanakumar RajendranChemistry Division, SAS, Vellore Institute of Technology, Chennai Campus, Chennai 600127, India.ORCID 0000-0002-7440-4038
Daniel BenharrochDepartment of Pathology, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel.ORCID 0000-0002-5178-5851
Jannat KhaliliaThe Shraga Segal Department of Microbiology, Immunology & Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel.
Haim LevyDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.ORCID 0000-0002-1902-8535
Elad Bar-DavidDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Avi Golan-GoldhirshThe Jacob Blaustein Institutes for Desert Research (BIDR), Ben-Gurion University of the Negev, Sede Boqer Campus, Sde Boker 8410501, Israel.
Jacob GopasThe Shraga Segal Department of Microbiology, Immunology & Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel.ORCID 0000-0001-9289-8898
Amir Ben-ShmuelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Ben-Gurion University of the Negev · ILIsrael Institute for Biological Research · ILVellore Institute of Technology University · IN
Funding
Israel Ministry of Health 3-0-7374
6 · The paper itself
Abstract
We have previously published research on the anti-viral properties of an alkaloid mixture extracted from
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
In Vitro and In Vivo Therapeutic Potential of 6,6'-Dihydroxythiobinupharidine (DTBN) from · full record | Socratic